New paper by Barbara Bailus and David Segal

Barbara Bailus, a Grad Student in David Segal's lab is the lead author on a new paper published this week in the journal BMC Neuroscience (provisional PDF only at this point). The paper The prospect of molecular therapy for Angelman syndrome and other monogenic neurologic disorders)  reviews the recent progress and prospect of targeted gene expression therapies. Co-author David Segal, who also holds positions in the MIND Institute, and the Department of Biochemistry and Molecular Medicine, had this to say about the paper:

"Most current treatments for neurological disorders focus on the management of symptoms rather than the underlying molecular cause of disease. Here we review the recent progress and prospect of targeted gene expression therapies, including artificial transcription factors. Three main issues that must be addressed to advance toward human clinical trials are specificity, toxicity, and delivery. We examine the possibilities of such approaches in the context of Angelman syndrome, as a template for other single-gene, neurologic disorders."